Related Experiment Videos
TIMI grade flow, mortality, and the GUSTO-III trial
1School of Pharmacy, University of Colorado Health Sciences Center, Denver 80262, USA.
Pharmacotherapy
|August 6, 1998
Summary
Thrombolytic therapy trials show improved survival for heart attack patients. However, recent studies question the "open-artery hypothesis" as improved blood flow did not significantly reduce mortality rates between different treatments.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Thrombolytic therapy has been used since the 1980s for acute myocardial infarction, with early trials showing survival benefits.
- The open-artery hypothesis suggests improved infarct-related artery patency enhances patient outcomes.
- Previous studies, like GUSTO-I, indicated a link between 90-minute TIMI grade 3 flow and reduced mortality.
Purpose of the Study:
- To evaluate the effectiveness of different thrombolytic agents in acute myocardial infarction.
- To assess the validity of the open-artery hypothesis by comparing mortality rates with varying levels of coronary artery patency.
Main Methods:
- Analysis of data from large-scale clinical trials, including GUSTO-I and GUSTO-III.
- Comparison of mortality rates and angiographic outcomes (TIMI grade 3 flow) between tissue plasminogen activator (tPA), streptokinase (SK), and reteplase (rPA).
Main Results:
- GUSTO-I showed higher 90-minute TIMI grade 3 flow with accelerated tPA versus SK, but a minimal difference in mortality.
- GUSTO-III found no significant difference in 30-day mortality between accelerated tPA and reteplase (rPA), despite anticipated differences based on flow rates.
- The absolute difference in mortality between agents was less than 1% in GUSTO-I and non-significant in GUSTO-III.
Conclusions:
- The results challenge the direct correlation between achieving 90-minute TIMI grade 3 flow and significant reductions in mortality.
- Further investigation is needed to understand why improved artery patency with thrombolytics does not consistently translate to greater mortality benefits.
- The clinical significance of achieving rapid and sustained artery patency requires re-evaluation in the context of thrombolytic therapy for myocardial infarction.